|9 Months Ended|
Sep. 30, 2021
5. Stockholders’ Equity
As of September 30, 2021, shares of the shares of the common stock grant had vested at approximately $value and shares remain unvested and unrecognized at approximately $value. An aggregate of shares of common stock were vested at approximately $ value in January through September 2021 in consideration for services rendered.
On January 29, 2021, in connection with our December 2020 follow-on offering, the underwriter exercised its option to purchase 2,800,000 and net proceeds of $2,548,000, after deducting underwriting discounts and commissions and offering expenses borne by the Company, which totaled $252,000. additional shares of common stock at the public offering price of $ per share for gross proceeds of $
At September 30, 2021, outstanding underwriter warrants to purchase shares of common stock accounted for as equity or liabilities were as follows with an aggregate intrinsic value as of September 30, 2021 of $ based on the September 30, 2021 closing share price of $ :
Schedule of Outstanding Warrants
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef